Lonza Group offers products and services including custom development and manufacturing of active pharmaceutical ingredients and innovative dosage forms for the pharmaceutical and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents, and other personal care ingredients, the company provides agricultural products, advanced coatings and composites, and microbial control solutions that combat dangerous viruses, bacteria, and other pathogens. Lonza opened a collaborative innovation center in Israel in 2017, which focuses on pharmaceutical and biotech research. The center serves as the company's link to local collaborations and partnerships with academic institutes, hospitals, and startups. In addition, Lonza has R&D activities in Israel, including a partnership with Sheba Medical Center to develop personalized cancer therapies. The company also collaborates with Israeli universities and research institutions to advance research in areas such as cell therapy, gene therapy, and vaccine development. Lonza's Technology & Innovation Center in Haifa, Israel, is focused on developing innovative solutions in areas such as drug delivery, bioconjugation, and bioanalytics. Overall, Lonza considers Israel to be an important location for its R&D activities and is committed to further expanding its presence in the country.